RemeGen Co

RemeGen Co Change in Working Capital

The Change in Working Capital of RemeGen Co (688331.SS) as of Nov 22, 2026 is -443.84 M CNY. In the previous year, Change in Working Capital was -169.50 M CNY — a change of 161.86% (lower).

Change in Working Capital

-443.84 MCNY

YoY

161.86%

Last updated:

Change in Working Capital of RemeGen Co is 2025 -443.84 M CNY. Change in Working Capital of RemeGen Co was 2024 -169.50 M CNY. It decreases by 161.86% lower compared to the previous year.

The RemeGen Co Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
73.97 M CNY
Jan 1, 2019
6.85 M CNY
Jan 1, 2020
-116.54 M CNY
Jan 1, 2021
-168.16 M CNY
Jan 1, 2022
-523.64 M CNY
Jan 1, 2023
-360.66 M CNY
Jan 1, 2024
-169.50 M CNY
Jan 1, 2025
-443.84 M CNY
The RemeGen Co Change in Working Capital history
YEARChange in Working CapitalYoY
-443.84 MCNY+161.86%
-169.50 MCNY-53.00%
-360.66 MCNY-31.12%
-523.64 MCNY+211.39%
-168.16 MCNY+44.30%
-116.54 MCNY-1,800.51%
6.85 MCNY-90.74%
73.97 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Change in Working Capital of RemeGen Co is -443.84 M CNY in 2025.

Change in Working Capital of RemeGen Co changed from -169.50 M CNY to -443.84 M CNY, representing a 161.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RemeGen Co

All Key Metrics — RemeGen Co